Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Karman Holdings is under fresh pressure this week, down 5.7% on Wednesday alone and 21% over the past month, with the Street still broadly bullish but quietly trimming its ambitions for the stock.
The most telling development is the gap between where analysts say the stock should trade and where it actually sits. The consensus price target has pulled back to $88.20, yet KRMN closed at $31.39. That gap reflects a series of downward revisions rather than irrational optimism. RBC Capital's Ken Herbert cut his target from $85 to $70 on September 28, maintaining an Outperform rating but acknowledging the stock's difficult trajectory. Earlier revisions were steeper: Truist slashed its target from $118 to $85 in August, Evercore ISI trimmed from $100 to $80, and Needham cut from $125 to $80. The direction of travel has been one-way for months. One outlier remains: BWS Financial holds a Sell rating with a $37 target, now barely above the current price, making it the closest thing to a consensus read on where the stock actually trades.
The bull case rests on the company's embedded position in DoD missile and space programs, claimed revenue visibility of roughly 95%, and 25% organic growth expectations through the end of the decade. Valuation has re-rated sharply with the stock: the PE multiple has compressed by nearly 12 points over 30 days to 36x, and EV/EBITDA has dropped roughly 1.5 points to 17.4x. Neither looks cheap for a company carrying $807 million in net debt and net leverage of 4.5x, rising to approximately 4.8x pro forma for the Walker acquisition. The bear case centers on customer concentration (three clients account for roughly half of FY25 revenue), the shift toward cost-plus contracts, and a cash position that fell to $51.7 million at the end of Q2 with free cash flow not yet positive. The factor score picture reinforces the caution: EPS momentum over 30 and 90 days ranks in the 84th to 87th percentiles, a genuine positive, but the short score rank sits in the bottom 6% of the universe.
Short positioning remains heavy and has not meaningfully unwound since last week's note. Short interest is 11.8% of the free float, around 15.6 million shares, essentially flat on the week but up 29% over the past month. The lending market remains relaxed about accommodating new shorts: availability runs at 218% of current short interest, well above the 52-week low of 77%, meaning there is no borrowing squeeze in view. Cost to borrow is 0.51%, up 8% on the week but still in the lowest tier by any measure. The ORTEX short score has eased slightly to 63.6 from 65.4 a week ago, a small move but worth noting given the stock's continued decline. Options positioning leans defensive. The put/call ratio is 1.38, above its 20-day mean of 1.19, though at less than one standard deviation above that average the reading is elevated rather than extreme.
Institutional flows add one layer of interest. BlackRock filed a fresh Schedule 13G on October 5, disclosing an 11.1% stake of 14.65 million shares, the first such filing and a substantial position. State Street and First Trust both added meaningfully in the quarter ending September 30. FMR trimmed from 6.3% to 5.2% over the same period. The Vanguard Group's 13G shows a position reduced to zero from 7.1%, filed in March. These are as-last-disclosed snapshots, and a holder dropping below 5% has no obligation to file again, so the picture is partial. Retail attention has also picked up: ORTEX's attention signal, which averages Wikipedia view z-scores against the company's own 90-day history, registered a reading of 3.1 as of late September, indicating materially elevated interest relative to its own recent baseline.
Earnings are due November 6. The two prior prints both generated positive one-day reactions, 12.7% and 5.6%, with five-day follow-through of 12.5% and 9.8% respectively. Whether the setup repeats will depend largely on whether management can demonstrate that free cash flow has turned positive in the second half, as previously guided, and whether the balance sheet trajectory has improved. Those two questions, cash generation and leverage direction, are the pivot points for a stock that the Street still officially likes but has been pricing lower every month.
See the live data behind this article on ORTEX.
Open KRMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
